Lantheus’ (LNTH) Neutral Rating Reaffirmed at Mizuho

Lantheus (NASDAQ:LNTH)‘s stock had its “neutral” rating reiterated by equities researchers at Mizuho in a note issued to investors on Tuesday, Benzinga reports. They presently have a $109.00 price target on the medical equipment provider’s stock, down from their prior price target of $115.00. Mizuho’s price target suggests a potential upside of 8.88% from the company’s current price.

LNTH has been the subject of several other reports. B. Riley Financial downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Citizens Jmp reissued a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and reduced their price target for the company from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Leerink Partners set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Lantheus has a consensus rating of “Hold” and an average price target of $107.44.

Lantheus Price Performance

Shares of LNTH stock opened at $100.11 on Tuesday. Lantheus has a twelve month low of $50.15 and a twelve month high of $111.86. The stock has a market capitalization of $6.53 billion, a price-to-earnings ratio of 24.18 and a beta of -0.06. The stock has a fifty day simple moving average of $100.47 and a two-hundred day simple moving average of $97.20. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The business’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.57 EPS. On average, analysts predict that Lantheus will post 4.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Diversified Management Inc. purchased a new stake in shares of Lantheus during the 3rd quarter worth $375,000. GAMMA Investing LLC boosted its position in Lantheus by 3.3% during the third quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider’s stock valued at $344,000 after purchasing an additional 109 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Lantheus by 122.9% during the third quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 306 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in Lantheus by 6.7% in the second quarter. Integrated Wealth Concepts LLC now owns 18,709 shares of the medical equipment provider’s stock valued at $2,076,000 after purchasing an additional 1,170 shares during the last quarter. Finally, Baird Financial Group Inc. grew its stake in Lantheus by 25.8% in the second quarter. Baird Financial Group Inc. now owns 29,356 shares of the medical equipment provider’s stock valued at $3,257,000 after purchasing an additional 6,013 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.